Business / Finance

RSS

OSI Systems reports revenues of $204 million for third quarter fiscal 2014

OSI Systems, Inc. today announced financial results for the third fiscal quarter ended March 31, 2014, including, among other things, the introduction of reporting Adjusted EBITDA, a discussion of which can be found below, under the caption, "New Presentation of Non-GAAP Financial Measure."

30 Apr 2014

Hospira’s net sales increase 6.3% to $1.1B in first quarter 2014

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2014.

30 Apr 2014

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

FitLife Brands reports record revenue of $6.3M in first quarter 2014

FitLife Brands, Inc., an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ (NDS), PMD®, SirenLabs® and CoreActive® today announced financial results for the first quarter ended March 31, 2014.

30 Apr 2014

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.

30 Apr 2014

LCA-Vision's revenues decrease $25.5M to 9.8% in first quarter 2014

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three months ended March 31, 2014.

30 Apr 2014

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

Denmark and China announce food safety partnership

On 25 April, a new memorandum of understanding between DTU and CFSA was signed by Martin Bends-e, DTU Senior Vice President and Dean, at a ceremony in Beijing witnessed by HRH Queen Margrethe II and Prince Henrik of Denmark.

30 Apr 2014

ICON Q1 2014 net revenue increases 10% to $349.6 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2014.

30 Apr 2014

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

InDevR Inc., a Boulder-based biotechnology company, and Applied Microarrays, Inc., a Tempe-based contract microarray manufacturer have partnered to deliver a complete system solution for multiplexed assays. The platform includes custom protein and DNA arrays, reagents and protocols, a fluorescent scanner for slides or plates (Vidia) and a colorimetric scanner for lower throughput applications (ampliPHOX).

30 Apr 2014

Cerus, Nipro partner to develop key component of INTERCEPT red cell disposable set

Cerus Corporation announced today that it has entered into a collaboration agreement with the Nipro Corporation's pharmaceutical division to develop technology to support commercial implementation of the INTERCEPT System for Red Blood Cells (RBCs).

29 Apr 2014

HCA Holdings Q1 2014 revenues up 4.6%

HCA Holdings, Inc. today announced financial and operating results for the first quarter ended March 31, 2014.

29 Apr 2014

Endo enters into definitive agreement to acquire Grupo Farmaceutico Somar

Endo International plc today announced it has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration. Endo expects the transaction to be immediately accretive to adjusted earnings per share.

29 Apr 2014

YourEncore announces partnership extension with Roche to provide expert solutions

YourEncore, a leading provider of expert solutions to the life sciences, consumer health and nutrition industries, today announced a partnership extension with Roche to provide expert solutions and services to support enhancing productivity and strengthening regulatory compliance.

29 Apr 2014

DJOFL first quarter 2014 net sales increase 1.3% to $282.7 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC, for the first quarter ended March 29, 2014.

29 Apr 2014

Doximity closes $54 million Series C fundraising round

Doximity, the professional network for doctors, today announced closing a $54 million Series C fundraising round co-led by DFJ and funds and accounts managed by T. Rowe Price Associates, Inc. Funds and accounts managed by Morgan Stanley Investment Management also participated in the round as new investors.

29 Apr 2014

Waters reports sales of $431 million for first quarter 2014

Waters Corporation reported today first quarter 2014 sales of $431 million, essentially flat versus sales of $430 million in the first quarter of 2013. In the quarter, the effect of foreign currency translation was neutral to sales growth.

29 Apr 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Magellan Health Services, Inc. today reported financial results for the first quarter 2014, as summarized below. For the quarter ended March 31, 2014, the company reported net revenue of $966.5 million, segment profit of $76.5 million, and net income of $25.7 million, or $0.92 earnings per share (EPS).

29 Apr 2014